Clinical Trial Synopsis TL-OPI-525, NCT#
|
|
- Angelica Clark
- 6 years ago
- Views:
Transcription
1 Clinical Trial Synopsis, NCT# Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS ) in Combination With TAK-536 in Subjects With Type 2 Diabetes Name of Sponsor: Takeda Global Research & Development Center, Inc. (TGRD) Name of Active Ingredient: Pioglitazone HCl (hereafter referred to as pioglitazone) in combination with TAK-536 Investigators: 127 investigators in the United States and Latin America Publication (reference): None Study Period (years): 28 July 2004 to 06 October 2005 Study Centers: 127 centers in the United States and Latin America Phase of Development: Phase 2 OBJECTIVES Primary: The primary objective of this study was to determine the effect of pioglitazone HC1 in combination with TAK-536 on glycemic control in subjects with type 2 diabetes. Secondary: The secondary objectives of this study were to determine the effects of pioglitazone in combination with TAK-536 on fasting plasma glucose (FPG), lipid profile, body weight, edema, systolic blood pressure (SBP) and diastolic blood pressure (DBP), microalbuminuria, and inflammatory markers (ie, high-sensitivity C-reactive protein [HS-CRP] and matrix metalloproteinase-9 [MMP-9]), and to determine the safety and tolerability of pioglitazone in combination with TAK-536. METHODOLOGY This was a phase 2, multicenter, randomized, parallel, double-blind, placebo-controlled, proof-of-concept study in subjects with moderately-controlled type 2 diabetes. Subjects received 15 mg of pioglitazone once daily (QD) for up to 6 days during the screening period (Screening). Eligible subjects were randomized to 1 of 6 double-blind treatment groups, and were instructed to take QD combinations of study drug over 24 weeks of treatment. The treatment groups were: Pioglitazone 15 mg plus placebo. Pioglitazone 15 mg plus TAK mg. Pioglitazone 15 mg plus TAK mg. Pioglitazone 45 mg plus placebo. Page 1 of 8
2 Pioglitazone 45 mg plus TAK mg. Pioglitazone 45 mg plus TAK mg. If a subject experienced intolerance, the investigator was able to reduce the number of tablets. Specifically, subjects were allowed to down-titrate from 40 mg to 20 or 10 mg of TAK-536 while maintaining the blind. Subjects in the placebo groups or TAK mg blinded dosing regimens were allowed to reduce the number of tablets but were not allowed to change the total daily dose. Number of Subjects: Planned: 660 subjects (110 per treatment group). Treatment Group: Analyzed: Intent-to-Treat Population Analyzed: Safety Population Pioglitazone 15 mg plus placebo: Pioglitazone 15 mg plus TAK mg: Pioglitazone 15 mg plus TAK mg: Pioglitazone 45 mg plus placebo: Pioglitazone 45 mg plus TAK mg: Pioglitazone 45 mg plus TAK mg: Diagnosis and Main Criteria for Inclusion: To qualify for study participation, subjects must have been subjects with type 2 diabetes; aged 18 years or older; been able to comprehend and willing to sign an informed consent form. The following additional inclusion criteria applied: The subject had a glycosylated hemoglobin A (A1C) value of greater than or equal to 8.0% or less than 10.0% at Screening. If the subject was receiving antihypertensive therapy, he or she must have been taking a stable dose for a minimum of 8 weeks prior to Screening. The subject had clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory unless the results were deemed not clinically significant by the investigator or sponsor. The subject had been on a stable diet and exercise program and oral antiglycemic therapy including sulfonylurea or metformin for 8 weeks prior to Screening. Test Product, Dose and Mode of Administration/Lot Number: TAK mg tablets, oral: TAK mg tablets, oral: Tablet Batch Number(s): Z Z556A022 Placebo for TAK-536 tablets: Z , Z , Z Duration of Treatment: The treatment duration included a 7-day Screening (pioglitazone 15 mg unblinded lead-in) and a 24-week double-blind treatment period. Page 2 of 8
3 Reference Therapy, Dose and Mode of Administration, Batch Number: Tablet Batch Number(s): Overencapsulated Tablet Batch Number(s) Pioglitazone 15 mg tablets, oral: Z59H , Pioglitazone 45 mg tablets, oral: P45345ZE, C , Criteria for Evaluation: Efficacy: The primary variable was the change from Baseline in A1C. The secondary variables were the changes from Baseline in FPG, lipid profile, body weight, edema (peripheral), SBP/DBP, microalbuminuria, and inflammatory markers (HS-CRP and MMP-9). Safety: The safety of pioglitazone plus TAK-536 was measured by the incidence of adverse events and by laboratory safety parameters. Statistical Methods: Efficacy parameters were analyzed using the intent-to-treat (ITT) population. The treatment comparisons for change from Baseline for A1C and other efficacy endpoints were carried out using 2-way analysis of covariance with terms for treatment and pooled center as factor and Baseline as covariate in the model. In addition to descriptive statistics, least-squares (LS) means were presented for change from Baseline by visit. Two-sided 95% confidence intervals (CIs) of the LS mean differences in endpoint change from Baseline between the active treatment groups and corresponding placebo were presented. Comparisons among the 6 treatment groups were provided. For HbA1c and weight, the primary analysis pooled across the pioglitazone (PIO) treatment groups (ie, Placebo + and, TAK mg + and 45 mg, and TAK mg + and 45 mg). Interactions between TAK-536 and PIO were to be investigated; if the interaction was statistically significant at the α=0.05 level, then treatment comparisons for each TAK-536 dose versus placebo were to be performed for Pioglitazone 15 mg and 45 mg separately. These comparisons were made using a 2-sided t-test. No adjustment was made for multiple comparisons. SUMMARY OF RESULTS Subject Disposition: A total of 704 subjects were randomized for treatment in 127 centers in the United States and Latin America. One hundred fifteen to 119 subjects were randomized to each of the 6 treatment groups, and 113 to 118 in each treatment group received double-blind medication. Six-hundred sixty-seven subjects were included in the ITT population. Subject Disposition is summarized in the following table. Page 3 of 8
4 Category Number of subjects discontinued from study Primary Reason for discontinuation PIO 15mg + Placebo PIO 15mg + TAK mg PIO 15mg + TAK mg 25 (21.0%) 23 (19.3%) 22 (19.1%) PIO 45mg +Placebo PIO 45mg + TAK mg PIO 45mg + TAK mg 14 (11.9%) 24 (20.3%) 19 (16.5%) Adverse Event (s) 1 (0.8%) 3 (2.5%) 2 (1.7%) 2 (1.7%) 6 (5.1%) 2 (1.7%) Lack of Efficacy 2 (1.7%) 6 (5.0%) 0 (0.0%) 1 (0.8%) 1 (0.8%) 1 (0.9%) Lost to Follow-Up 5 (4.2%) 3 (2.5%) 8 (7.0%) 1 (0.8%) 4 (3.4%) 1 (0.9%) Investigator 1 (0.8%) 0 (0.0%) 0 (0.0%) 1 (0.8%) 2 (1.7%) 3 (2.6%) Discretion Study Terminated 1 (0.8%) 3 (2.5%) 3 (2.6%) 4 (3.4%) 1 (0.8%) 1 (0.9%) Protocol Violation 4 (3.4%) 1 (0.8%) 1 (0.9%) 3 (2.5%) 2 (1.7%) 0 (0.0%) Voluntary 8 (6.7%) 4 (3.4%) 5 (4.3%) 2 (1.7%) 6 (5.1%) 9 (7.8%) Withdrawal (by patient) Pregnancy 1 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Other 2 (1.7%) 3 (2.5%) 3 (2.6%) 0 (0.0%) 2 (1.7%) 2 (1.7%) Demographic and Other Baseline Characteristics No significant differences were observed across the treatment groups for any demographic characteristics, except for the proportion of male and female subjects within different treatment groups (P=0.006). Demographic data are summarized in the following table. Page 4 of 8
5 Characteristic Sex +Placebo (N=111) Male, n (%) 64 (57.7) Female, n (%) 47 (42.3) Mean age, yr (SD) Race American Indian or Alaskan Native, n (%) 56.3 (11.14) 12 (10.8) Asian, n (%) 1 (0.9) Black or African American, n (%) 9 (8.1) Multiracial, n (%) 3 (2.7) White, n (%) 86 (77.5) Mean BMI (SD) 30.4 (4.82) Mean A1C (SD) 8.81 (0.730) Mean SBP (SD) (13.86) Mean DBP (SD) 78.8 (8.30) 5 mg (N=114) 42 (36.8) 72 (63.2) 58.7 (10.59) 14 (12.3) 0 (0.0) 7 (6.1) 3 (2.6) 90 (78.9) 29.0 (4.85) 8.86 (0.634) (12.47) 79.7 (8.44) 40 mg (N=105) 42 (40.0) 63 (60.0) 56.1 (10.52) 6 (5.7) 0 (0.0) 6 (5.7) 3 (2.9) 90 (85.7) 30.6 (4.73) 8.82 (0.708) (14.41) 79.5 (7.44) Treatment +Placebo (N=113) 63 (55.8) 50 (44.2) 56.3 (10.90) 14 (12.4) 0 (0.0) 10 (8.8) 1 (0.9) 88 (77.9) 29.9 (4.60) 8.72 (0.787) (13.37) 78.4 (7.85) 5 mg (N=114) 50 (43.9) 64 (56.1) 56.3 (10.89) 14 (12.3) 1 (1.9) 10 (8.8) 3 (2.6) 86 (75.4) 30.4 (5.07) 8.96 (0.772) (13.32) 80.6 (7.86) 40 mg (N=110) 50 (45.5) 60 (54.5) 56.1 (11.04) 13 (11.8) 1 (0.9) 10 (9.1) 2 (1.8) 84 (76.4) 29.8 (4.19) 8.90 (0.731) (12.33) 79.0 (7.37) Efficacy Results: The therapeutic effect observed in clinical trials of a drug cannot be directly compared to the effects found in clinical trials of other drugs and may not reflect the therapeutic effects observed in practice. In addition, therapeutic effects observed in a single clinical trial may not reflect the overall therapeutic effects observed in all clinical trials of a drug. The primary variable was change from Baseline in A1C. As shown in the following table, greater reductions in A1C were observed when pioglitazone was coadministered with TAK or 40 mg compared to pioglitazone only. At 16 and 20 weeks of treatment, the treatment differences (in LS mean change from Baseline) were statistically significantly greater for pioglitazone plus TAK mg compared to pioglitazone plus placebo, based on the pooled analysis of pioglitazone groups. Page 5 of 8
6 Visit Change From Baseline in A1C (%) (Pooled Pioglitazone Groups) PIO+Placebo PIO 5 mg PIO 40 mg N=224 N=228 N=215 Baseline (a) 8.78 (0.052) 8.90 (0.050) 8.88 (0.052) Week 12 (b) (0.090) (0.089) (0.092) Week 16 (b) (0.094) (0.092) -1.29* (0.096) Week 20 (b) (0.099) (0.097) -1.36* (0.101) Week 24 (b) (0.101) (0.099) (0.102) Treatment effect (c) (-0.3, 0.3) (-0.5, 0.0) (a) LS mean (standard error). (b) LS mean change from Baseline (standard error). (c) LS mean difference from placebo at Week 24 (CI). *=Statistically significant at P<0.05. Subgroups of subjects with moderately poor to poor glycemic control (Screening A1C values 8% or 9%, respectively) were analyzed without regard to pioglitazone dose. In these analyses, the combination of pioglitazone (either dose) plus TAK mg reduced A1C by 0.32% or 0.60%, respectively, compared to pioglitazone alone. The addition of TAK or 40 mg to pioglitazone reduced FPG levels at all weeks measured (up to 40.0 mg/dl). However, no statistically significant differences were observed in the comparisons of TAK-536 with matching placebo treatments. Comparison of pioglitazone 15 mg plus TAK mg treatment with pioglitazone 45 mg plus placebo treatment showed statistically significant FPG reductions at Weeks 6, 8, and 24 (P 0.037). Treatment with pioglitazone 15 or 45 mg alone (ie, the 2 placebo groups) reduced fasting plasma insulin levels at both weeks measured (up to 3.6 µiu/ml), as did addition of TAK or 40 mg to each pioglitazone regimen in most instances (up to 2.8 µiu/ml). A statistically significant difference in the comparison of pioglitazone 45 mg plus TAK mg treatment with the matching placebo treatment was observed at Week 12 (P=0.024). Comparison of pioglitazone 15 mg plus TAK mg treatment with pioglitazone 45 mg plus placebo treatment showed a significant difference at Week 12 (P 0.008). Microalbuminuria was decreased from Baseline to the final visit by all TAK-536 treatments (up to 52.8 mg/dl), but not by treatment with either dose of pioglitazone alone. Statistically significantly significant reductions from Baseline were observed with both TAK mg groups compared with matching placebo treatments (P 0.016). In the pooled analysis of pioglitazone groups, statistically significant mean increases in body weight (up to 2.76 kg) were observed at Weeks 6, 12, and 20 for the PIO + TAK mg group compared with PIO + placebo (P 0.035). By Week 8, treatment with pioglitazone 15 mg plus TAK or 40 mg achieved statistically significant reductions in sitting DBP (up to 6.3 mmhg) that persisted through Week 24 compared with matching placebo treatments (P 0.049). By Week 2, treatment with pioglitazone 45 mg plus TAK or 40 mg resulted in statistically significant reductions (up to 5.6 mmhg) at all weeks (except Week 8 for TAK mg) compared with matching placebo treatments (P 0.016). By Week 6, treatment with pioglitazone 15 mg plus TAK or 40 mg achieved statistically significant reductions in sitting SBP (up to 8.0 mmhg) that persisted through Week 24 compared with matching placebo treatments (P 0.033). By Week 2, treatment with pioglitazone 45 mg plus TAK or 40 mg resulted in statistically significant reductions (up to 9.2 mmhg) at all weeks (except Week 8 for TAK mg) compared with matching placebo treatments (P 0.028). No statistically significant treatment differences were observed for lipid parameters (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), peripheral edema, or the inflammatory markers HS-CRP and MMP-9 for any treatment group. Page 6 of 8
7 Safety Results: Adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice. In addition, the rates observed in a single clinical trial may not reflect the overall rates observed in all clinical trials of a drug. A total of 422 subjects experienced adverse events in the study (approximately 60% of subjects in each treatment group). Between 22.9% and 36.8% of subjects in each treatment group experienced adverse events considered by the investigator to be related to study medication. The majority of adverse events were considered by the investigator to be mild or moderate in severity. The incidence of adverse events that occurred in at least 5% of subjects it any treatment group is summarized in the following table. Treatment n (%) System Organ Class Preferred Term + Placebo N=118 5 mg N= mg N=113 +Placebo N=118 5 mg N= mg N=114 Any adverse event 68 (57.6) 76 (64.4) 69 (61.1) 68 (57.6) 68 (58.1) 73 (64.0) Gastrointestinal disorders Diarrhea 7 (5.9) 9 (7.6) 7 (6.2) 6 (5.1) 9 (7.7) 4 (3.5) Abdominal pain 3 (2.5) 2 (1.7) 4 (3.5) 6 (5.1) 3 (2.6) 1 (0.9) Constipation 0 2 (1.7) 0 1 (0.8) 3 (2.6) 6 (5.3) General disorders and administration site conditions Edema peripheral 6 (5.1) 9 (7.6) 5 (4.4) 6 (5.1) 10 (8.5) 10 (8.8) Infections and infestations Influenza 3 (2.5) 6 (5.1) 4 (3.5) 8 (6.8) 8 (6.8) 6 (5.3) Nasopharyngitis 6 (5.1) 2 (1.7) 1 (0.9) 5 (4.2) 7 (6.0) 4 (3.5) Pharyngitis 4 (3.4) 2 (1.7) 1 (0.9) 6 (5.1) 2 (1.7) 3 (2.6) Urinary tract 2 (1.7) 2 (1.7) 1 (0.9) 3 (2.5) 8 (6.8) 5 (4.4) infection Investigations Weight increased 1 (0.8) 1 (0.8) 4 (3.5) 2 (1.7) 6 (5.1) 2 (1.8) Metabolism and nutrition disorders Hypoglycemia 1 (0.8) 6 (5.1) 2 (1.8) 4 (3.4) 6 (5.1) 4 (3.5) Musculoskeletal and connective tissue disorders Arthralgia 4 (3.4) 9 (7.6) 2 (1.8) 4 (3.4) 9 (7.7) 6 (5.3) Back pain 4 (3.4) 6 (5.1) 2 (1.8) 4 (3.4) 4 (3.4) 7 (6.1) Nervous system disorders Headache 7 (5.9) 10 (8.5) 11 (9.7) 12 (10.2) 8 (6.8) 8 (7.0) Dizziness 4 (3.4) 11 (9.3) 13 (11.5) 5 (4.2) 4 (3.4) 14 (12.3) Respiratory, thoracic, and mediastinal disorders Cough 5 (4.2) 1 (0.8) 3 (2.7) 4 (3.4) 3 (2.6) 7 (6.1) Vascular disorders Hypotension 0 4 (3.4) 6 (5.3) 1 (0.8) 4 (3.4) 9 (7.9) Page 7 of 8
8 Twenty-four subjects experienced serious adverse events during the study. SAEs that occurred in more than 1 subject were hypoglycemia (4 subjects), myocardial infarction (2 subjects), and cerebrovascular incident (2 subjects). Five SAEs were considered by the investigator to be related to study medication: hypoglycemia (2 subjects), cholelithiasis, cholecystitis, and syncope. Thirty-two subjects (4.6%) discontinued the study due to an adverse event. Adverse events that led to study discontinuation in more than 1 subject were vision blurred (3 subjects), edema peripheral (3 subjects), dizziness (3 subjects), diarrhea (2 subjects), dyspepsia (2 subjects), weight increased (2 subjects), hyperglycemia (2 subjects), and headache (2 subjects). Two deaths, sudden cardiac death (pioglitazone 45 mg plus TAK mg) and hemorrhagic stroke (pioglitazone 15 mg plus placebo), were reported in the study; neither death was considered related to study drug. Date of Synopsis: 28 October 2008 draft Page 8 of 8
Clinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationSponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia
Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSynopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationSponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationInvestigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD
STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationClinical Trial Results Disclosure Synopsis
Clinical Trial Results Disclosure Synopsis Short Title: The SPLENDOR study Name of Sponsor: Takeda Italia S.p.A. Via Elio Vittorini, 129 00144 Rome, Italy Title of Study: Effects of Pioglitazone on endothelial
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00492011 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00671398 Title of Study: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model
More information24-Week CNTO1275PSA3001 Clinical Study Report
24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationTo assess the safety and tolerability in each treatment group.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationSponsor. Novartis. Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Type 2 diabetes.
Sponsor Page 1 Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLAF237A2308 Title A multicenter, randomized, double-blind,
More informationClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Sanofi-Aventis ClinicalTrials.gov
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Caduet / Amlodipine
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Niaspan Name of Active Ingredient: Page: Niacin extended-release
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationEfficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationFinal Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110
BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationIndividual Study Table Referring to Part of the Dossier. Use only) Name of Finished Product:
SYNOPSIS Fresenius Title of the study: A double-blind, randomized study comparing the safety and torelance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition Coordinating
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationSupplemental Information. The Sustained Effects of a Dual. GIP/GLP-1 Receptor Agonist, NNC , in Patients with Type 2 Diabetes
Cell Metabolism, Volume 26 Supplemental Information The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Juan Pablo Frias, Edward J. Bastyr, III, Louis
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTHERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information